Clinical trials: Depressed
Major Depressive Disorder
The Study of Olanzapine Plus Fluoxetine in Combination for Treatment of Treatment Resistant Depression
The purposes of this study are to determine: Whether olanzapine plus fluoxetine in combination will help patients with treatment-resistant major depression.
- Trial name
- NCT00035321
- Testing
- Olanzapine, Fluoxetine
- Where
- 33 sites in United States, Canada
- Volunteers
- 600 people
- Sponsor
- Eli Lilly and Company
Bipolar Disorder, Bipolar Depression
Quetiapine XR Versus Sertraline in Acute Bipolar Depression as add-on Therapy
Prospective, open-label, controlled (active comparator), randomized study of 8 weeks follow-up for the evaluation of the efficacy of extended release quetiapine (quetiapine XR) versus Sertraline in addition to previous mood…
- Trial name
- NCT00857584
- Testing
- Extended release quetiapine (quetiapine XR), Sertraline, adequate mood stabilizer
- Where
- 4 sites in Spain
- Volunteers
- 27 people
- Sponsor
- AstraZeneca
Depression, Major Depressive Disorder
Effect of SSRIs on Response to Psilocybin Therapy
This study is an open-label, single-arm, within-subjects design in individuals with mild-moderate Major Depressive Disorder (MDD). All participants will receive a single dose of 25mg of psilocybin in a therapeutic setting.
- Conditions
- Depression, Major Depressive Disorder, Mild Depression, Moderate Depression
- Trial name
- NCT05594667
- Testing
- Psilocybin
- Where
- Canada
- Sponsor
- Cybin Therapeutics Inc.
Major Depressive Disorder
Major Depressive Disorder With Mixed Features
Lurasidone HCl is a compound that is a candidate for the treatment of major depressive with mixed features.This clinical study is designed to test how well Lurasidone works to treat major depressive disorder with mixed features.
- Trial name
- RESOLVE2 (NCT01423240)
- Testing
- Lurasidone 20 mg, Lurasidone 60 mg
- Where
- 27 sites in United States
- Sponsor
- Sumitomo Pharma America, Inc.
Major Depressive Disorder
Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy in Patients With Major Depressive Disorder
The objective of this study is to evaluate the long-term safety and tolerability of cariprazine as an adjunctive treatment to antidepressant therapy (ADT) in patients with Major Depressive Disorder (MDD).
- Trial name
- NCT01838876
- Testing
- Cariprazine, Antidepressant Therapy (ADT)
- Where
- 90 sites in United States, Puerto Rico
- Volunteers
- 442 people
- Sponsor
- Forest Laboratories
Psychological, Depression, Anxiety
The Effects of a Life Coaching Seminar on Gratitude and Psychological Well-Being
This study will consist of a randomized experimental group and a control group, In addition to the control and experimental group, there will also be a non-randomized motivated experimental group.
- Conditions
- Psychological, Depression, Anxiety, Psychological Stress, Mental Health Wellness 1
- Trial name
- NCT04172051
- Testing
- Tony Robbins Date with Destiny
- Where
- 3 sites in United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Applied Science & Performance Institute
Major Depressive Disorder
Efficacy and Safety of Vortioxetine (Lu AA21004) in the Treatment of Patients With Major Depressive Disorder
The purpose of this study is to determine the efficacy and safety of vortioxetine, once daily (QD), in adults with major depressive disorder.
- Trial name
- NCT00672620
- Testing
- Vortioxetine, Duloxetine
- Where
- 38 sites in United States
- Volunteers
- 611 people
- Sponsor
- Takeda
Depression
Predicting Response to Depression Treatment (PReDicT)
Depression is a very common, serious and in some cases life-threatening condition, affecting around 350 million people globally.
- Trial name
- NCT02790970
- Testing
- PReDicT Test, Treatment as Usual
- Where
- 76 sites in France, Germany and 3 more
- Volunteers
- 913 people
- Sponsor
- P1vital Products Limited
Treatment-Resistant Depression
NRX-101 Expanded Access
The purpose of this Expanded Access Treatment Protocol is to make NRX-101 available to patients who have treatment-resistant depression and who are unable to participate in, or do not have access to, the ongoing NRX-101 clinical…
- Trial name
- NRX-101 EAP (NCT05779267)
- Testing
- NRX-101
- Where
- United States
- Sponsor
- NeuroRx, Inc.
Depression, Major Depressive Disorder
Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) In The Treatment Of Child And Adolescent Outpatients With Major Depressive Disorder
The primary purpose of this study is to test the safety and tolerability of single ascending doses of Desvenlafaxine Succinate Sustained-Release (DVS SR) in both child and adolescent outpatients with major depressive disorder.
- Trial name
- NCT00619619
- Testing
- Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR)
- Where
- 9 sites in United States
- Volunteers
- 59 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Major Depressive Disorder
Vortioxetine Intravenous Infusion at Initiation of Oral Treatment With Vortioxetine in Patients With Depression
The purpose of this study is to evaluate the efficacy and safety of vortioxetine given as a single intravenous dose of 25 mg at initiation of an oral vortioxetine regimen of 10 mg/day for 7 days
- Trial name
- NCT03766867
- Testing
- Vortioxetine infusion 25 mg, Vortioxetine tablets 10 mg/day
- Where
- 13 sites in Bulgaria, Estonia and 1 more
- Volunteers
- 80 people
- Sponsor
- H. Lundbeck A/S
Bipolar Depression
Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Bipolar Depression
The purpose of the study is to determine the efficacy, safety and pharmacokinetics of inhaled Esketamine in participants with treatment-resistant bipolar depression (TRBD).
- Trial name
- NCT03965871
- Testing
- Esketamine DPI - low dose, Esketamine DPI - medium dose, Esketamine DPI - high dose
- Where
- 12 sites in Poland
- Volunteers
- 88 people
- Sponsor
- Celon Pharma SA
Depression
Single Ascending Dose Study of NH102 in Healthy Subjects
The purpose of this study is to assess the safety, tolerability and pharmacokinetics (PK) of NH102 when administered as single oral dose at escalating dose levels in healthy participants.
- Trial name
- NCT05015192
- Testing
- NH102
- Where
- China
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Jiangsu Nhwa Pharmaceutical Co., Ltd.
Bipolar II Disorder
Phase 2 Clinical Trial of GH001 in Bipolar II Disorder
This study is a multicenter, open-label, single-arm Phase 2 clinical trial. Approximately 15 participants with clinically diagnosed bipolar disorder (BD) type II and experiencing a current episode of depression will be included…
- Trial name
- NCT05839509
- Testing
- GH001
- Where
- 7 sites in Germany, Netherlands and 1 more
- Volunteers
- 6 people
- Sponsor
- GH Research Ireland Limited
Major Depressive Disorder
Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder
The purpose of this study is to determine the effectiveness and safety of vortioxetine, once daily (QD), in patients with Major Depressive Disorder.
- Trial name
- NCT00735709
- Testing
- Vortioxetine
- Where
- 48 sites in Australia, Czechia and 13 more
- Volunteers
- 560 people
- Sponsor
- Takeda
Major Depressive Disorder
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
This is a double-blind study evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) versus placebo in the Treatment of Children and Adolescent Outpatients with Major Depressive Disorder (MDD).
- Trial name
- NCT01371734
- Testing
- Desvenlafaxine Succinate Sustained-Release
- Where
- 42 sites in United States, Chile and 1 more
- Volunteers
- 363 people
- Sponsor
- Pfizer
Major Depressive Disorder (MDD
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Characteristics of (R)-Ketamine Hydrochloride Nasal Spray in Patients With Depression and Acute Suicidal Ideation or Behavior
The purpose of this study is to learn about: To evaluate the efficacy of PRT-042 nasal spray for the Rapid Reduction of the depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or…
- Trial name
- NCT07193901
- Testing
- Low Dose PRT042 nasal spray, median Dose PRT042 nasal spray, high dose PRT042 nasal spray
- Where
- 15 sites in China
- Volunteers
- 98 people
- Sponsor
- Sichuan Purity Pharmaceutical Technology Co., Ltd.
Multiple Myeloma
A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg
1. Planned enrollment period One year (The planned number of patients to be enrolled is set to 400 patients.) Since all patients who are prescribed with Pomalyst are registered in RevMate®, enrollment using the Registration Form…
- Trial name
- NCT02921828
- Where
- 2 sites in United States, Japan
- Volunteers
- 1,149 people
- Sponsor
- Celgene
Depression
Using Computer Tasks to Predict Response to Antidepressants
In England over 800,000 patients each year are either newly diagnosed with depression or present with a new episode of depression in primary care.
- Trial name
- NCT02800577
- Testing
- General Practitioner Emotional Test Battery (GP-ETB)
- Where
- 10 sites in United Kingdom
- Volunteers
- 80 people
- Sponsor
- P1vital Products Limited
Major Depressive Disorder
NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
The study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.
- Trial name
- NCT06911112
- Testing
- NBI-1065845
- Where
- 39 sites in United States, Bulgaria and 3 more
- Volunteers
- 200 people
- Sponsor
- Neurocrine Biosciences